|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LETTER |
Jacqueline Sherris and John W. Sellors are with PATH, Seattle, Wash. Thomas C. Wright, Jr is with the Department of Pathology, Columbia University, New York, NY. Lynette Denny is with the Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town, South Africa. Rengaswamy Sankaranarayanan is with the International Agency for Research on Cancer Screening Group, Lyon, France. Amy E. Pollack is with the Mailman School of Public Health, Columbia University, New York. Harshad Sanghvi is with JHPIEGO, Baltimore, Md.
Correspondence: Requests for reprints should be sent to Jacqueline Sherris, PhD, PATH, 1455 Leary Way NW, Seattle, WA 98117 (e-mail: sherries@path.org).
|
|||
The recently published article by Suba et al.1 advocates for expanded access to Papanicolaou testing worldwide and for analysis of obstacles to effective screening programs. We are pleased to see discussion of this important topic in the Journal.
Suba et al. criticized the work of the Alliance for Cervical Cancer Prevention (ACCP), an alliance of 5 organizations with a goal of reducing cervical cancer deaths among the worlds poorest women. The article repeats previous criticisms the authors have made,2 including about the safety of visual screening approaches, the ethics of several ACCP studies, the assertion that ACCP leaders are "loath
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |